Details for Patent: 9,539,218
✉ Email this page to a colleague
Which drugs does patent 9,539,218 protect, and when does it expire?
Patent 9,539,218 protects XARELTO and is included in one NDA.
Protection for XARELTO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-nine patent family members in twenty-five countries.
Summary for Patent: 9,539,218
| Title: | Prevention and treatment of thromboembolic disorders |
| Abstract: | The present invention relates to the field of blood coagulation, more specifically it relates to a method of treating a thromboembolic disorder by administering once daily a direct factor Xa inhibitor in oral dosage form to a patient in need thereof, wherein the factor Xa inhibitor has a plasma concentration half life indicative of a bid or tid administration interval, e.g. of 10 hours or less. |
| Inventor(s): | Misselwitz; Frank (Heidelberg, DE), Kubitza; Dagmar (Ratingen, DE), Park; Son-Mi (Wuppertal, DE), Wehling; Klaus (Wuppertal, DE) |
| Assignee: | BAYER INTELLECTUAL PROPERTY GMBH (Monheim am Rhein, DE) |
| Application Number: | 11/883,218 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,539,218 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 9,539,218
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Pharms | XARELTO | rivaroxaban | TABLET;ORAL | 022406-001 | Jul 1, 2011 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Janssen Pharms | XARELTO | rivaroxaban | TABLET;ORAL | 022406-002 | Nov 4, 2011 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Janssen Pharms | XARELTO | rivaroxaban | TABLET;ORAL | 022406-003 | Nov 4, 2011 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,539,218
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 05001893 | Jan 31, 2005 | |
| PCT Information | |||
| PCT Filed | January 19, 2006 | PCT Application Number: | PCT/EP2006/000431 |
| PCT Publication Date: | August 03, 2006 | PCT Publication Number: | WO2006/079474 |
International Family Members for US Patent 9,539,218
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 052565 | ⤷ Sign Up | |||
| Argentina | 110413 | ⤷ Sign Up | |||
| Australia | 2006208613 | ⤷ Sign Up | |||
| Brazil | PI0606760 | ⤷ Sign Up | |||
| Canada | 2596145 | ⤷ Sign Up | |||
| China | 101111236 | ⤷ Sign Up | |||
| Cyprus | 1116494 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
